Associate Director, Study Toxicologist

Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. Madrigal Pharmaceuticals is seeking an Associate Director, Study Toxicologist to support nonclinical development programs for metabolic dysfunction–associated steatohepatitis (MASH). This role focuses on the execution and scientific oversight of outsourced nonclinical studies supporting regulatory-stage development programs, partnering closely with Nonclinical Development program leads to ensure studies support regulatory submissions and clinical development. The successful candidate will support studies across toxicology, pharmacokinetics (PK), ADME, and bioanalytical disciplines, working with contract research organizations (CROs) and internal teams to deliver high-quality data aligned with program timelines. The role will support a range of nonclinical studies, including IND-enabling and later-stage safety studies, as programs progress through development. This role is part of the Nonclinical Development team within Research, supporting Madrigal’s growing MASH portfolio and providing opportunities over time to contribute more broadly to nonclinical development strategy. **Key Responsibilities** **Study Design & Oversight** - Support the design and execution of nonclinical studies, including toxicology, PK, ADME, and bioanalytical studies. - Provide scientific oversight of outsourced studies, including protocol input, study monitoring, data review, and final report review. **CRO & Study Management** - Coordinate study placement and management at CROs, including vendor interaction, study startup, and timeline tracking. - Monitor study conduct at external vendors to ensure quality and alignment with program timelines and objectives. **Data Review & Collaboration** - Review and interpret study data and reports for accuracy, completeness, and scientific rigor. - Partner closely with Nonclinical Development program leads and cross-functional teams to support integrated development plans and contribute scientific input to nonclinical development strategy as appropriate. - Maintain clear communication with internal stakeholders and external partners throughout study execution. **Qualifications** **Required** - PhD (or equivalent) in Toxicology, Pharmacology, DMPK, or a related scientific discipline. - Relevant pharmaceutical or biotechnology industry experience supporting nonclinical development programs and 10+ years of relevant experience. - Experience managing outsourced nonclinical studies with CROs, including protocol and report review. - Strong attention to detail and ability to manage multiple studies simultaneously. - Excellent written and verbal communication skills. **Preferred** - Experience with small molecule and/or siRNA programs. - Experience supporting late-stage nonclinical studies, including reproductive and developmental toxicology (DART) and carcinogenicity studies. Madrigal’s Total Rewards strategy is based…